. sgRNAs targeting genes in KEGG-defined pyrimidine metabolism pathway were significantly decreased after 14 days of cell culture. The average of 1,000 non-targeting sgRNAs was used as control. of four gastric cancer cell lines. Grey dots indicated non-targeting sgRNAs, and yellow dots indicated genes with log 2 (fold change)<-0.5 and p<0.05. Genes involved in one carbon pool by folate and KEGG-defined pyrimidine metabolism pathways were shown in blue dots. 1,000 non-targeting sgRNAs were used as control in all the four independent screening. Fig. 5 . JQ1 significantly reduced the cell viability of SNU-1 and NUGC3 cell lines. (a) Immunoblotting analysis of the protein expression levels of MYC and thymidylate synthase in SNU-1 and NUGC3 after 1 μM JQ1 treatment for 72 hours. (b) The relative cell viability of SNU-1 and NUGC3 after the treatment of indicated drugs. 10 μM RTX and 10 μM JQ1 were used to achieve the maximal inhibition.
a Supplementary Fig. 4 . MYC and NIPBL are discretely mutated in both stomach and colorectal adenocarcinomas of TCGA provisional database. There're 53 MYC-amplified, 48 NIPBL-mutated and 4 TYMS-amplified cases in 393 stomach adenocarcinomas, and 14 MYC-amplified, 14 NIPBL-mutated and 3 TYMS-mutated cases in 220 colorectal adenocarcinomas. Tumour samples of TCGA provisional database with both mutation and copy number alternations were used in this study, without accounting NIPBL-amplified cases. Supplementary Fig. 7 . The relative MYC and TYMS mRNA expression levels of HCT116 cells to NUGC3 cells. The mRNA expression levels were detected by q-PCR, normalized by GAPDH. 
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